 |
市場調查報告書
商品編碼
1085609
復發性多形性膠質母細胞瘤治療市場：按治療、按類型、按區域規模、份額、前景、機會分析-2022-2028Recurrent Glioblastoma Multiforme Treatment Market, by Treatment, by Type, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028 |
||||||
價格
簡介目錄
在預測區間內，預計腦腫瘤發病率的增加將推動治療復發性膠質母細胞瘤復發性息肉的市場增長。市場上的領先公司正在加大對研發的投入，以開發、創造和商業化新藥，並有望在不久的將來為全球市場創造有利的增長機會。然而，缺乏有效的治療方法和有效預防腫瘤復發的藥物預計將限制預測區間內的市場增長。
本報告對複發性多形性膠質母細胞瘤治療的全球市場進行研究和分析，並提供有關市場促進者、抑制者、市場機會、治療方法/類型/區域市場分析和企業概況的信息。
目錄
第 1 章調查目標/先決條件
第二章市場概述
- 報告說明
- 市場定義和範圍
- 執行摘要
- 市場細分：按處理方法
- 市場細分：按類型
- 市場細分：按地區
- 連貫的機會圖 (COM)
第三章市場動態、監管和趨勢分析
- 市場動態
- 促進因素
- 抑制器
- 市場機會
- 影響分析
- 復發性膠質母細胞瘤多態性治療的技術進展
- 主要發展
- 收購、合作、夥伴關係
- 流行病學
- 贖回分析
- 管道分析
- 價格分析
- 處理算法
第 4 章全球復發性多形性膠質母細胞瘤市場：COVID-19 的影響
- COVID 之前的狀態
- 疫情過後的需求
- 需要一種治療復發性膠質母細胞瘤多態性的藥物
- 建議和指南：由監管機構提供
第 5 章全球治療□□復發性多形性膠質母細胞瘤的市場：按治療（2017-2028 年（100 萬美元））
- 簡介
- 口服藥
- 放射增敏劑
- 亞硝基尿類藥物
- 化療
第 6 章全球治療□□復發性多形性膠質母細胞瘤的市場：按類型（2017-2028 年（100 萬美元））
- 簡介
- 二級或三級
- 四級
- 其他
第 7 章全球復發性多形性膠質母細胞瘤治療市場：按地區劃分（2017-2028 年（100 萬美元））
- 簡介
- 北美
- 歐洲
- 亞太地區
- 拉丁美洲
- 非洲
- 中東
第8章競爭態勢
- 公司簡介
- GlaxoSmithKline, Plc.
- Astrazeneca
- F. Hoffman-La Roche, Ltd.
- Pfizer, Inc.
- Merck & Co., Inc.
- Vascular Biogeneics
- AngioChem, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Boston Biomedical, Inc.
- Cantex Pharmaceuticals, Inc.
- Celldex Therapeutics, Inc.
- Cavion LLC
- Coherus BioSciences, Inc.
- Eisai
- Eli Lilly and Company
- Cortice Biosciences, Inc.
- EnGeneIC Ltd.
- GenSpera, Inc.
- ERC Belgium SA
- Genzyme Corporation
- ImmunoCellular Therapeutics, Ltd.
- GW Pharmaceuticals Plc.
第9章 章節
簡介目錄
Product Code: CMI682
Glioblastoma multiforme or GBM is an aggressive and the most common form of brain cancer that involves glial cells. Gliomas are rapidly developing tumors that develop from the star-shaped glial cells present in the spinal cord or brain. Recurrent glioblastoma multiforme is a possibility of reoccurrence of GBM after tumor surgery. This is because it is difficult to wholly remove the tumor during surgery and there is always a possibility that after a period of remission, cancer might recur. The symptoms of GBM include constant headaches, seizures, vomiting, difficulty in speaking, and double or blurred vision.
Market Dynamics
The rising incidence of brain cancers is expected to drive the recurrent glioblastoma multiforme treatment market growth over the forecast period. Although, researchers believe that egentic mutations may cause this disease, symptoms include seizures, change in mood, loss of appetite, double or blurred vision, change in ability to think and difficulty in speech. According to the statistics provided by the World Health Organization (WHO), each year, around 5 million people are diagnosed with epilepsy across the globe.
Moreover, tuberous sclerosis, neurofibromatosis, von-hippel-lindau disease, turcot syndrome, and Li-fraumeni syndrome are some of the genetic disorders related to the increasing prevalence of gliomas, which is expected to fuel the market growth during the forecast period.
Furthermore, key players in the market are increasingly investing in research & development to develop, create, and commercialize novel drugs, which is expected to create lucrative growth opportunities for the global recurrent glioblastoma multiforme treatment market in the near future. However, lack of effective therapies and the inability of drugs to effectively prevent tumor reoccurrence are predicted to restrict the market growth over the forecast period.
Key features of the study:
- This report provides in-depth analysis of the global recurrent glioblastoma multiforme treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
- It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global recurrent glioblastoma multiforme treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
- Key players covered as a part of this study include GlaxoSmithKline plc., AstraZeneca, F. Hoffman-La Roche, Ltd., Pfizer, Inc., Merck & Co., Inc., Vascular Biogeneics, AngioChem, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Cantex Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Cavion LLC, Coherus BioSciences, Inc., Eisai, Eli Lilly and Company, Cortice Biosciences, Inc., EnGeneIC Ltd., GenSpera, Inc., ERC Belgium SA, Genzyme Corporation, ImmunoCellular Therapeutics, Ltd., and GW Pharmaceuticals Plc.
- Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global recurrent glioblastoma multiforme treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for recurrent glioblastoma multiforme treatment market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
- Global Recurrent Glioblastoma Multiforme Treatment Market, By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- Global Recurrent Glioblastoma Multiforme Treatment Market, By Type:
- Grade II or Grade III
- Grade IV
- Others
- Global Recurrent Glioblastoma Multiforme Treatment Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- By Type:
- Grade II or Grade III
- Grade IV
- Others
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- By Type:
- Grade II or Grade III
- Grade IV
- Others
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- By Type:
- Grade II or Grade III
- Grade IV
- Others
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- By Type:
- Grade II or Grade III
- Grade IV
- Others
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- By Type:
- Grade II or Grade III
- Grade IV
- Others
- Africa
- By Region:
- North Africa
- Central Africa
- South Africa
- By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- By Type:
- Grade II or Grade III
- Grade IV
- Others
- North America
- Company Profiles
- GlaxoSmithKline, Plc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Astrazeneca
- F. Hoffman-La Roche, Ltd.
- Pfizer, Inc.
- Merck & Co., Inc.
- Vascular Biogeneics
- AngioChem, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Boston Biomedical, Inc.
- Cantex Pharmaceuticals, Inc.
- Celldex Therapeutics, Inc.
- Cavion LLC
- Coherus BioSciences, Inc.
- Eisai
- Eli Lilly and Company
- Cortice Biosciences, Inc.
- EnGeneIC Ltd.
- GenSpera, Inc.
- ERC Belgium SA
- Genzyme Corporation
- ImmunoCellular Therapeutics, Ltd.
- GW Pharmaceuticals Plc.
- GlaxoSmithKline, Plc.
"*" marked represents similar segmentation in other categories in the respective section
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment
- Market Snippet, By Type
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Technological Advancements in Recurrent Glioblastoma Multiforme Treatment
- Key Developments
- Acquisition, Collaborations & Partnerships
- Epidemiology
- Reimbursement Analysis
- Pipeline Analysis
- Pricing Analysis
- Treatment Algorithm
4. Global Recurrent Glioblastoma Multiforme Treatment Market, Impact of Coronavirus (Covid-19) Pandemic
- Pre-COVID Situation
- Post-COVID Demand
- Need for Recurrent Glioblastoma Multiforme Treatment
- Recommendations and Guidelines by Regulatory Bodies
5. Global Recurrent Glioblastoma Multiforme Treatment Market, By Treatment, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Oral Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Radiosensitizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Nitrosoureas Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
6. Global Recurrent Glioblastoma Multiforme Treatment Market, By Type, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Grade II or Grade III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Grade IV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
7. Global Recurrent Glioblastoma Multiforme Treatment Market, By Region, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
- Regional Trends
- North America
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- GCC
- Israel
- Rest of Middle East
8. Competitive Landscape
- Company Profiles
- GlaxoSmithKline, Plc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Astrazeneca
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- F. Hoffman-La Roche, Ltd.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Merck & Co., Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Vascular Biogeneics
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AngioChem, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Boehringer Ingelheim GmbH
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Boston Biomedical, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cantex Pharmaceuticals, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Celldex Therapeutics, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cavion LLC
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Coherus BioSciences, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Eisai
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Eli Lilly and Company
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cortice Biosciences, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- EnGeneIC Ltd.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GenSpera, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- ERC Belgium SA
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Genzyme Corporation
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- ImmunoCellular Therapeutics, Ltd.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GW Pharmaceuticals Plc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
9. Section
- References
- Research Methodology
- About us and Sales Contact
02-2729-4219
+886-2-2729-4219
